Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

  1. Ravassa, S.
  2. López, B.
  3. Ferreira, J.P.
  4. Girerd, N.
  5. Bozec, E.
  6. Pellicori, P.
  7. Mariottoni, B.
  8. Cosmi, F.
  9. Hazebroek, M.
  10. Verdonschot, J.A.J.
  11. Cuthbert, J.
  12. Petutschnigg, J.
  13. Moreno, M.U.
  14. Heymans, S.
  15. Staessen, J.A.
  16. Pieske, B.
  17. Edelmann, F.
  18. Clark, A.L.
  19. Cleland, J.G.F.
  20. Zannad, F.
  21. Díez, J.
  22. González, A.
Revista:
European Journal of Heart Failure

ISSN: 1879-0844,  1388-9842

Any de publicació: 2022

Volum: 24

Número: 2

Pàgines: 321-331

Tipus: Article

DOI: 10.1002/EJHF.2394 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus